<DOC>
	<DOC>NCT01200394</DOC>
	<brief_summary>PF-00489791 is an inhibitor of phosphodiesterase type 5. Our hypothesis is that PF-00489791 will enhance the relaxation of blood vessels within the kidney and so reduce blood pressure, improving renal function.</brief_summary>
	<brief_title>A Phase 2, Placebo-Controlled Study To Evaluate The Efficacy And Safety Of PF-00489791 In Patients With Type 2 Diabetes And Overt Nephropathy</brief_title>
	<detailed_description />
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Diabetic Nephropathies</mesh_term>
	<mesh_term>Phosphodiesterase 5 Inhibitors</mesh_term>
	<criteria>Male or female subjects greater than or equal to 18 years. Female subjects must be of nonchild bearing potential. Clinical diagnosis of type 2 diabetes together with stages 3a, 3b or 4 CKD, based on an eGFR of 2559 mL/min/1.73m2. Evidence of persistent, overt albuminuria; defined as a UACR greater than or equal to 300 mg/g (greater than or equal to 33.9 mg/mmol) for greater than 3 months. Subjects with CKD resulting from type 1 diabetes or nondiabetic CKD. Subjects with poorly controlled diabetes mellitus, defined as HbA1C &gt;9%. Subjects on combination ACE inhibitor/ARB therapy.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2014</verification_date>
	<keyword>Diabetic nephropathy</keyword>
	<keyword>chronic kidney disease</keyword>
	<keyword>PF-00489791</keyword>
	<keyword>phosphodiesterase</keyword>
	<keyword>PDE5</keyword>
</DOC>